In a powerful show of community health advocacy, Guardant Health and the Dolphins Cancer Challenge (DCC) joined forces Saturday to host a groundbreaking colorectal cancer (CRC) screening event at Hard Rock Stadium’s Dolphins Fan Zone. The initiative, timed ahead of the Dolphins-Jaguars preseason matchup, spotlighted the importance of early detection and offered attendees access to ShieldTM, the first FDA-approved blood test for CRC screening.
The Shield test, developed by Guardant Health, allows eligible individuals to be screened for colorectal cancer with a simple blood draw, an innovation that could reshape how communities approach cancer prevention.
“CRC is the second leading cause of cancer-related deaths in the United States, yet it has an impressive 91 percent five-year survival rate when caught in its early stages, which is why screening and early detection are crucial,” said Guardant Health Vice President of Clinical Development for Screening Dr. Sam Asgarian. “By bringing the Shield test directly to the Miami community here at Hard Rock Stadium, we’re taking a positive step toward breaking down barriers to screening through a non-invasive blood test and reaching people who might not otherwise get tested.”
Among those screened was Miami Dolphins legend Nat Moore, who shared his personal commitment to proactive health care and encouraged others to follow suit.
“Taking care of my health has always been a priority, and as I’ve grown older, I’ve come to understand just how critical regular screenings are, especially for cancers like colon cancer. That’s why I didn’t hesitate to get screened myself,” Moore said. “I’m proud to lead by example and stand with so many in the South Florida community who are stepping up to take control of their health through early detection and innovative screening methods, such as the Shield test.”
The event is part of a larger mission by Guardant Health and the DCC to close the CRC screening gap and support cancer research. The DCC continues to be a driving force in South Florida’s fight against cancer.
Adults aged 45 and older are encouraged to speak with their healthcare providers about CRC screening options or visit https://shieldcancerscreen.comfor more information.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
